FDA‑cleared SDK Leverage DeepWell DTx’s FDA-cleared software development kit that combines vagal nerve stimulation and breath mechanics to offer over-the-counter mental health and stress treatments, creating a compelling selling point for partners seeking regulatory‑backed digital therapeutics integration.

Gaming meets therapy Position the company to gaming and media platforms by highlighting the ability to embed therapeutic outcomes into interactive experiences, enabling scalable mental health solutions that align with game progression and engagement metrics.

NEUFluent collaboration Explore partnerships through NeuFluent to accelerate commercialization and scale innovations, using their neurotechnology ecosystem to expand reach, credibility, and access to additional distribution channels.

Targeted markets Focus on sectors combining media/content creators with health outcomes, such as wellness apps, streaming platforms, and educational games, where DeepWell’s SDK can shorten clearance cycles and unlock new monetization models.

Funding signals Note revenue under $1M but with strategic tech assets and regulatory clearance; pitch investors and partners on low‑cost, scalable deployment of neurotech‑driven digital therapeutics in consumer channels and enterprise wellness programs.